{"id":"b3768681df0f","type":"article","url":"https://hartvaat.nl/2022/08/09/vertraagde-afgifteformulering-van-ivabradine-bij-systolisch-hartfalen/","title":"Vertraagde-afgifteformulering van ivabradine bij systolisch hartfalen","title_en":"Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["hfref","ivabradine"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.05.027","source_url":"https://doi.org/10.1016/j.jacc.2022.05.027","authors":["Feiming Ye","Xiaofeng Wang","Shulin Wu","Shumei Ma","Yu Zhang","Gang Liu","Kunshen Liu","Zhiming Yang","Xiaohua Pang","Li Xue","Shijuan Lu","Ming Zhong","Jing Li","Hao Yu","Donghua Lou","Dongyang Cui","Xiaojie Xie","Jian'an Wang"],"significance":6,"published":"2022-08-09","source_date":"2022-08-09","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This study of a sustained-release ivabradine formulation in systolic heart failure demonstrated that once-daily dosing achieves comparable heart rate reduction to the twice-daily formulation, potentially improving adherence.","created":"2026-07-03T10:29:52Z","updated":"2026-07-03T18:38:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie onderzocht een vertraagde-afgifteformulering van ivabradine bij HFrEF die éénmaal daags gedoseerd kan worden. Het preparaat toonde vergelijkbare hartfrequentieverlagende werking als de tweemaal daagse formulering, wat de therapietrouw kan verbeteren.","abstract_original":"BACKGROUND: Ivabradine has potent actions in reducing heart rate and improving clinical outcomes of chronic heart failure with reduced ejection fraction (HFrEF). At present, only the short-acting formulation of ivabradine is available that needs to be administered twice daily. OBJECTIVES: This study sought to evaluate the role of ivabradine hemisulfate sustained release (SR), a novel long-acting formulation of ivabradine dosed once daily, in stable patients with HFrEF. METHODS: Patients with stabilized HFrEF in New York Heart Association functional class II-IV were enrolled and randomized to receive placebo or ivabradine SR in addition to standard medications. The primary endpoint was the change of left ventricular (LV) end-systolic volume index from baseline to week 32. RESULTS: We randomly assigned 181 patients to placebo and 179 patients to ivabradine SR. After 32 weeks, a significant improvement of LV end-systolic volume index from baseline was observed in both arms with a greater effect in the ivabradine SR arm. Ivabradine SR therapy also exhibited superiority in improving LV end-diastolic volume index, LV ejection fraction, resting heart rate, the Kansas City Cardiomyopathy Questionnaire score, and hospital admission for heart failure worsening and cardiovascular disease in comparison to placebo. Overall adverse events showed no difference between the treatment arms. There were fewer occurrences of worsening heart failure in the ivabradine SR arm. CONCLUSIONS: The present study demonstrates that ivabradine SR once daily in addition to optimum standard therapy improved heart function in patients with HFrEF. (Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets [FIRST]; NCT02188082)."}